Skip to main content
Premium Trial:

Request an Annual Quote

LGC Biosearch Technologies Gets FDA Emergency Use Authorization for SARS-CoV-2 Test

This article has been updated from a previous version to clarify language about the March 2020 authorization granted to kits supplied by LGC Biosearch.

NEW YORK — The US Food and Drug Administration on Thursday granted Emergency Use Authorization for a PCR-based SARS-CoV-2 test developed by LGC Biosearch Technologies, a Petaluma, California-based division of UK-headquartered LGC.

The Biosearch Technologies SARS-CoV-2 Real-Time and End-Point RT-PCR Test is designed to detect the N gene of the virus in samples collected by a healthcare provider, including anterior nasal, midturbinate nasal, nasopharyngeal, or oropharyngeal swabs, as well as nasopharyngeal washes/aspirates or nasal aspirates. It runs on LGC Biosearch's IntelliQube qPCR instrument.

The test may be used by any lab CLIA-certified to perform high-complexity tests, according to the FDA.

In March 2020, LGC Biosearch Technologies noted that it was supplying Emergency Use Authorized SARS-CoV-2 testing kits developed by the US Centers for Disease Control and Prevention.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.